ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2025
Long-term effect of transcatheter mitral valve edge-to-edge repair on left ventricular function and mitral regurgitation severity: a single-center experience.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term outcomes of transcatheter mitral valve edge-to-edge repair (TEER) are compared with medical therapy remain under investigation. This study evaluated the 3-year effects of MitraClip on mitral regurgitation (MR) severity, ventricular remodeling, and clinical outcomes in high surgical-risk patients.
methodsA single-center retrospective cohort included 31 MitraClip patients (2016-2023) and 30 contemporaneous controls on maximally tolerated guideline-directed medical therapy. Anatomical suitability was based on EVEREST criteria. Echocardiography was performed at baseline, 1, 2, and 3 years. Outcomes included MR severity, left ventricular ejection fraction (LVEF), right-sided parameters, biomarkers, NYHA class, 6-min walk test, heart failure (HF) hospitalizations, and all-cause mortality.
resultsMean age was 63.2 ± 14.5 MitraClip vs. 72.1 ± 8.9 years controls, with secondary MR in 61.3% vs. 56.7%. Severe pulmonary hypertension (SPAP > 50 mmHg) was present in 25% of primary and 55% of secondary MR patients. No procedural mortality occurred. MR improved significantly with MitraClip (93.0% mild to moderate at 1st year, 83.9% at 3rd year) while controls remained severe (p < 0.001). LVEF remained stable (~ 33-35%, p = 0.412) without correlation to MR reduction. HF hospitalizations were lower with MitraClip (58.1%, 2.1 ± 1.8 admissions) vs. controls (7.6 ± 3.2, p < 0.001). Within MitraClip, secondary MR patients had higher rates (68.4% vs. 41.7%, p = 0.042). SPAP decreased after MitraClip but rose in controls (p = 0.015). BNP declined with MitraClip but increased in controls (p = 0.01). At 3 years, more MitraClip patients were in NYHA I/II (41.9% vs. 15%), 6MWT improved while controls declined, and mortality was lower (12.9% vs. 45%, p < 0.01).
conclusionTEER provides durable MR reduction, BNP stabilization, improved functional capacity, and survival benefits compared with medical therapy in high-risk surgical patients. Primary MR patients might derive greater benefit than those with secondary MR. Larger multicenter studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.